Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.47 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.36 |
| ▸ | NR2E1 | Q9Y466 | 4/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832580 | 0.90 | ALPL (0.54) | ALPLPLAAALPGLMNAALDH1A1 | |
| SCHEMBL28043323 | 0.87 | ALPL (0.49) | ALPLPLAAALPGLMNAALDH1A1 | |
| SCHEMBL11997951 | 0.75 | ALPL (0.54) | ALPLPLAAALPGALDH1A1NR2E1 | |
| SCHEMBL15485019 | 0.75 | ALDH1A1 (0.39) | LMNAALDH1A1KDM4EAKR1B1 | |
| SCHEMBL1178916 | 0.74 | ALPL (0.53) | ALPLPLAAALPGLMNARAB9A | |
| SCHEMBL3711683 | 0.73 | RAB9A (0.54) | ALPLPLAAALPGLMNAALDH1A1 | |
| SCHEMBL2961993 | 0.71 | ALPL (0.50) | ALPLPLAAALPGALDH1A1KDM4E | |
| SCHEMBL10223628 | 0.71 | ALDH1A1 (0.39) | ALPLPLAAALPGLMNAALDH1A1 | |
| SCHEMBL4969959 | 0.71 | ALPL (0.65) | ALPLPLAAALPGKDM4ESMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL3583791 | 0.71 | KDM4E (0.39) | ALPLPLAAALPGLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | ALPL 4236/4885PLAA 3390/4885ALPG 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.